Breast ReconstructionNCT07842406
A Clinical Study Evaluating the Safety and Performance of Eurosilicone Integrated Valve Tissue Expanders (IVTE)
An observational study of Breast Reconstruction and Mammary Reconstruction, run by GCA (Eurosilicone).
Trial summary
Patients can undergo breast reconstruction surgery in two stages before implantation of the permanent prosthesis for several reasons. In order to confidently state safety and due to strict regulation on medical devices it is important to maintain a record of safety and performance with all medical implants. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Reconstruction, Mammary Reconstruction
- What is being tested?
- Breast reconstruction surgery
- Type of treatment
- Medical device
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Oct 2026to Oct 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Women over 18 years old who underwent a two-stage breast reconstruction with Eurosilicone integrated valve tissue expander.
Who may be able to join
- • Subjects aged ≥18
- Subjects who underwent single or bilateral breast implantation with the study device for one of the following reasons:
- Reconstruction of the breast following subcutaneous mastectomy and other mastectomy procedures or trauma.
- Breast underdevelopment and combined breast and chest wall abnormalities.
- Scar/defect revision
- Subjects who have received a Eurosilicone IVTE.
Who cannot join
- Subjects with contra-indication to the surgery or not filling Instruction for Use (IFU) indications, contra-indications.
About this study
Official title: A Retrospective, Multi-center, Observational, Post-marketing Surveillance Study to Obtain Clinical Outcome Data on the Eurosilicone IVTE Range of Silicone Breast Expanders When Used for Breast Reconstruction.
Patients can undergo breast reconstruction surgery in two stages before implantation of the permanent prosthesis for several reasons. In order to confidently state safety and due to strict regulation on medical devices it is important to maintain a record of safety and performance with all medical implants.
This study is designed to collect data on Integrated valve tissue expander to assess the performance and safety data on this device.
- Conditions
- Breast Reconstruction, Mammary Reconstruction
- Being tested
- Breast reconstruction surgery
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Breast reconstruction surgeryDevice
The tissue expander is inserted during the first surgery and expanded with sterile solution. After 6 months (or less), the tissue expander is removed and the brest implant is inserted during the second surgery.
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of reconstruction failure
Reconstruction failure means that the definitive reconstructive surgery (breast implant or autologous reconstruction) either did not take place or was unsuccessful.
Measured: 2 years after the tissue expander implantation surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2026
- Study startOct 2026 (estimated)
- Primary completionOct 2027 (estimated)
- Study completionOct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast ReconstructionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- GCA (Eurosilicone)
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07842406
- Sponsor's protocol ID
- CLA-0024
- Status last verified
- Sep 2026
- First submitted
- 14 Sep 2026
- Last updated
- 25 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No